NRDL outlook survey

Question Title

* 1. What is your read of the 2020 NRDL overall?

Exciting

Depressing

Not sure

Please provide rationale.

Question Title

* 2. Is the number of new additions of 119 in line with your expectations?

More than expected

Less than expected

More or less in line

Please provide rationale.

Question Title

* 3. Is the average price cut magnitude of 51% in line with your expectation?

More than expected

Less than expected

More or less in line

Please provide rationale.

Question Title

* 4. What do you see as the key success factors for 2020 NRDL inclusion?

Internal alignment and preparation

Key stakeholder engagements

Price concession magnitude

Clinical value of the drug

Social economic value of the drug

Others

Please provide rationale.

Question Title

* 5. Who do you see as the key stakeholders for 2020 NRDL inclusion besides the NHSA (National Healthcare Security Administration)

Shortlist review experts: Generalists (综合组评审专家)

Shortlist review experts: Clinicians (临床组评审专家)

Pharmacoeconomics evaluation experts (药物经济学组专家)

Budget impact evaluation experts (基金测算专家)

Negotiation experts (谈判专家)

Others

Please provide rationale.

Question Title

* 6. What do you see as the most important evidences needed to be furnished for 2020 NRDL inclusion?

IRP (International reference pricing)

TA (therapeutic area) comparator reference

Clinical data

HEOR data (e.g. ICER, QALY, RWE)

Budget impact data

Others

Please provide rationale.

Question Title

* 7. What new payment models are likely to emerge in future NRDL?

Outcome based pricing

Total cost capping

Patient number capping

Cost capping per patient

DRG

Others

Please provide rationale.

Question Title

* 8. What are the keys for internal alignment and preparations?

Organization effectiveness

Clear roles and responsibilities

Process efficiency

Global and China alignment

Competence and expertise

Others

Please provide rationale.

NRDL outlook survey

Question Title

* 1. What is your read of the 2020 NRDL overall?

Question Title

* 2. Is the number of new additions of 119 in line with your expectations?

Question Title

* 3. Is the average price cut magnitude of 51% in line with your expectation?

Question Title

* 4. What do you see as the key success factors for 2020 NRDL inclusion?

Question Title

* 5. Who do you see as the key stakeholders for 2020 NRDL inclusion besides the NHSA (National Healthcare Security Administration)

Question Title

* 6. What do you see as the most important evidences needed to be furnished for 2020 NRDL inclusion?

Question Title

* 7. What new payment models are likely to emerge in future NRDL?

Question Title

* 8. What are the keys for internal alignment and preparations?

Question Title

* 9. Your email to receive our analysis